Gynipral (Hexoprenaline Sulfate)

Gynipral is indicated for situations where suppression of uterine contractions is clinically required.

• Management of preterm labor to delay delivery.
• Treatment of uterine tachysystole during labor induction.
• Adjunct therapy in obstetric procedures requiring uterine relaxation.
• Short‑term use when rapid inhibition of uterine activity is needed.
• Off‑label use may include experimental protocols under research settings.

The safety profile of Gynipral includes both frequently observed and less common adverse reactions.

Common

• Tremor or shaking.
• Palpitations or increased heart rate.
• Nausea.

Serious

• Significant arrhythmias.
• Severe hypotension.
• Allergic reactions including rash or anaphylaxis.

When prescribing Gynipral, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

• Use only under continuous cardiac and fetal monitoring.
• Contraindicated in patients with known hypersensitivity to hexoprenaline or related beta‑2 agonists.
• Caution in individuals with cardiovascular disease, especially arrhythmias or hypertension.
• Avoid in uncontrolled hyperthyroidism.
• Assess blood glucose in diabetic patients, as beta‑2 stimulation may affect glycemic control.
• Limit duration of therapy to the shortest effective period.

Gynipral may interact with other medications that influence cardiovascular or smooth‑muscle function.

Avoid

• Concurrent use with non‑selective beta‑blockers, which can diminish tocolytic effect.
• Combination with other potent vasodilators, increasing risk of hypotension.

Use with caution

• Concurrent administration of other beta‑2 agonists (e.g., terbutaline) may enhance side‑effects.
• Drugs that affect electrolyte balance, such as diuretics, may increase risk of cardiac arrhythmias.
• Anticoagulants, because uterine relaxation may alter bleeding risk.